Former NIH scientist sues Trump administration, claims illegal firing over research cuts

The U.S. Department of Health and Human Services has announced a series of regulatory actions aimed at effectively banning gender-affirming care for minors, which includes prohibiting Medicaid funding for puberty blockers, hormone treatments, and surgical procedures. This proposal has been met with significant backlash from advocates for LGBTQ+ rights and healthcare professionals.

U.S. officials, under the Trump administration, are proposing new regulations that would effectively ban gender-affirming care for minors, including prohibiting Medicaid funding for treatments such as puberty blockers and hormone therapies. This move has sparked significant concern among healthcare professionals and advocates for LGBTQ+ rights.

The Trump administration has initiated steps to eliminate transition-related care for transgender minors, which the Department of Health and Human Services (HHS) has classified as 'sex-rejecting procedures.' This move is part of a broader regulatory effort to restrict access to gender-affirming treatments, including Medicaid funding for puberty blockers and hormone therapies.

The Trump administration has proposed two new rules aimed at banning gender-affirming care for minors, leveraging Medicare and Medicaid regulations to restrict access to treatments for transgender youth. This initiative, announced by RFK Jr. and Dr. Oz, is expected to impact not only those using public insurance but also those with private coverage.